With Zepbound approved for sleep apnea, Lilly spends up to $7.8 billion for a company with a narcolepsy drug

by | Mar 31, 2026 | Stock Market

The company, which is flush with cash from sales of its market-leading GLP-1 franchise, has been an active dealmaker.

Article Attribution | Read More at Article Source